CSL Limited Sponsored ADR (OTCMKTS:CSLLY) Short Interest Update

CSL Limited Sponsored ADR (OTCMKTS:CSLLY) was the recipient of a significant growth in short interest in June. As of June 30th, there was short interest totaling 394,744 shares, a growth of 82.3% from the June 15th total of 216,478 shares. Based on an average daily trading volume, of 1,137,720 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.0% of the shares of the stock are sold short.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on CSLLY shares. Canaccord Genuity Group cut CSL from a “strong-buy” rating to a “hold” rating in a report on Monday, May 11th. Zacks Research downgraded shares of CSL from a “hold” rating to a “strong sell” rating in a research note on Monday, May 11th. Jefferies Financial Group lowered CSL from a “strong-buy” rating to a “hold” rating in a research report on Friday, May 29th. Finally, Citigroup cut CSL from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 11th. Four equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce”.

CSL Stock Performance

Shares of CSL stock opened at $21.43 on Friday. CSL has a 12 month low of $16.01 and a 12 month high of $44.85. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.15 and a current ratio of 2.57. The stock’s fifty day moving average price is $18.99 and its 200-day moving average price is $33.20.

About CSL

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines.